AnnJi Pharmaceutical Co., Ltd. (TPEX:7754)
24.35
-0.50 (-2.01%)
Jun 20, 2025, 2:59 PM CST
AnnJi Pharmaceutical Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 629.04 | 597.86 | 267.9 | 391.41 |
Short-Term Investments | 76 | 274 | - | - |
Trading Asset Securities | 0.97 | 5.51 | - | - |
Cash & Short-Term Investments | 706.01 | 877.37 | 267.9 | 391.41 |
Cash Growth | -19.53% | 227.50% | -31.55% | - |
Accounts Receivable | 0.15 | - | 0.09 | - |
Other Receivables | 1.03 | 3.92 | 12.49 | 10.51 |
Receivables | 1.17 | 3.92 | 12.58 | 10.51 |
Inventory | 27.42 | - | 4.89 | 5.31 |
Prepaid Expenses | 9.2 | 37.54 | 20.14 | 4.95 |
Total Current Assets | 743.8 | 918.82 | 305.51 | 412.18 |
Property, Plant & Equipment | 76.4 | 82.08 | 6.73 | 11.18 |
Long-Term Investments | 79.2 | 69.78 | 59.4 | 39.6 |
Other Intangible Assets | 100.6 | 134.57 | 168.75 | 202.74 |
Other Long-Term Assets | 2 | 2.74 | 0.84 | 0.84 |
Total Assets | 1,002 | 1,208 | 541.23 | 666.54 |
Accounts Payable | 0.12 | - | - | - |
Accrued Expenses | 48.39 | 48.09 | 27 | 11.7 |
Current Portion of Leases | 5.98 | 5.8 | - | 2.79 |
Current Income Taxes Payable | 40.66 | 38.08 | - | - |
Current Unearned Revenue | 192.73 | 126.09 | 1.6 | - |
Other Current Liabilities | 2.67 | 9.55 | 2.12 | 1.76 |
Total Current Liabilities | 290.54 | 227.6 | 30.72 | 16.25 |
Long-Term Leases | 49.36 | 55.34 | - | - |
Other Long-Term Liabilities | - | - | - | 0.16 |
Total Liabilities | 339.9 | 282.94 | 30.72 | 16.41 |
Common Stock | 936.92 | 908.61 | 658.76 | 623.76 |
Additional Paid-In Capital | 961.07 | 909.67 | 426.15 | 384.49 |
Retained Earnings | -1,300 | -946.02 | -616.8 | -380.15 |
Comprehensive Income & Other | 64.11 | 52.78 | 42.4 | 22.03 |
Shareholders' Equity | 662.1 | 925.04 | 510.51 | 650.13 |
Total Liabilities & Equity | 1,002 | 1,208 | 541.23 | 666.54 |
Total Debt | 55.34 | 61.13 | - | 2.79 |
Net Cash (Debt) | 650.67 | 816.24 | 267.9 | 388.62 |
Net Cash Growth | -20.28% | 204.68% | -31.06% | - |
Net Cash Per Share | 7.00 | 10.55 | 4.08 | 8.60 |
Filing Date Shares Outstanding | 93.69 | 90.86 | 65.88 | 45.2 |
Total Common Shares Outstanding | 93.69 | 90.86 | 65.88 | 45.2 |
Working Capital | 453.26 | 691.22 | 274.79 | 395.93 |
Book Value Per Share | 7.07 | 10.18 | 7.75 | 14.38 |
Tangible Book Value | 561.5 | 790.47 | 341.76 | 447.39 |
Tangible Book Value Per Share | 5.99 | 8.70 | 5.19 | 9.90 |
Machinery | 33.77 | 35.05 | 36.36 | 36.24 |
Construction In Progress | - | 8.03 | - | - |
Leasehold Improvements | 16.94 | 7.58 | 4.28 | 4.28 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.